BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 16489080)

  • 1. Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology.
    Gerber B; Krause A; Reimer T; Mylonas I; Makovitzky J; Kundt G; Janni W
    Clin Cancer Res; 2006 Feb; 12(4):1245-50. PubMed ID: 16489080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: baseline endometrial sub-protocol data on the effectiveness of transvaginal ultrasonography and diagnostic hysteroscopy.
    Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Pollard S; Clack G; Coibion M; Bianco AR;
    Hum Reprod; 2005 Jan; 20(1):294-301. PubMed ID: 15513977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of endometrial thickness in hormone receptor positive early stage breast cancer postmenopausal women switching from adjuvant tamoxifen treatment to anastrozole.
    Valenzano Menada M; Costantini S; Moioli M; Bogliolo S; Papadia A; Ferrero S; Dugnani MC
    Breast; 2008 Dec; 17(6):631-6. PubMed ID: 18606545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data.
    Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Pollard S; Clack G; Cuzick J; Coibion M; Bianco AR
    BJOG; 2003 Dec; 110(12):1099-106. PubMed ID: 14664881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transvaginal sonographic and hysteroscopic findings in postmenopausal women receiving tamoxifen.
    Marconi D; Exacoustos C; Cangi B; Perroni A; Zupi E; Valli E; Romanini C
    J Am Assoc Gynecol Laparosc; 1997 May; 4(3):331-9. PubMed ID: 9154782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
    Jakesz R; Jonat W; Gnant M; Mittlboeck M; Greil R; Tausch C; Hilfrich J; Kwasny W; Menzel C; Samonigg H; Seifert M; Gademann G; Kaufmann M; Wolfgang J;
    Lancet; 2005 Aug 6-12; 366(9484):455-62. PubMed ID: 16084253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound.
    Gerber B; Krause A; Müller H; Reimer T; Külz T; Makovitzky J; Kundt G; Friese K
    J Clin Oncol; 2000 Oct; 18(20):3464-70. PubMed ID: 11032586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
    Boccardo F; Rubagotti A; Puntoni M; Guglielmini P; Amoroso D; Fini A; Paladini G; Mesiti M; Romeo D; Rinaldini M; Scali S; Porpiglia M; Benedetto C; Restuccia N; Buzzi F; Franchi R; Massidda B; Distante V; Amadori D; Sismondi P
    J Clin Oncol; 2005 Aug; 23(22):5138-47. PubMed ID: 16009955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial.
    Thürlimann B; Hess D; Köberle D; Senn I; Ballabeni P; Pagani O; Perey L; Aebi S; Rochlitz C; Goldhirsch A
    Breast Cancer Res Treat; 2004 Jun; 85(3):247-54. PubMed ID: 15111763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.
    Aapro MS; Forbes JF
    Breast Cancer Res Treat; 2003; 80 Suppl 1():S3-11; discussion S13-8. PubMed ID: 14535530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in postmenopausal breast cancer patients using tamoxifen.
    Mourits MJ; Van der Zee AG; Willemse PH; Ten Hoor KA; Hollema H; De Vries EG
    Gynecol Oncol; 1999 Apr; 73(1):21-6. PubMed ID: 10094875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endometrial evaluation in postmenopausal breast cancer patients receiving tamoxifen: an ultrasound, color flow Doppler, hysteroscopic and histological study.
    Exacoustos C; Zupi E; Cangi B; Chiaretti M; Arduini D; Romanini C
    Ultrasound Obstet Gynecol; 1995 Dec; 6(6):435-42. PubMed ID: 8903921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment.
    Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Pollard S; Clack G; Coibion M; Bianco AR
    Hum Reprod; 2006 Feb; 21(2):545-53. PubMed ID: 16210385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indication of hysteroscopy in tamoxifen treated breast cancer patients.
    Taponeco F; Curcio C; Fasciani A; Giuntini A; Artini PG; Fornaciari G; Petraglia F; Genazzani AR
    J Exp Clin Cancer Res; 2002 Mar; 21(1):37-43. PubMed ID: 12071527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.
    Buzdar AU;
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):399-403. PubMed ID: 14623537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen.
    Fung MF; Reid A; Faught W; Le T; Chenier C; Verma S; Brydon E; Fung KF
    Gynecol Oncol; 2003 Oct; 91(1):154-9. PubMed ID: 14529676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors.
    Garuti G; Cellani F; Centinaio G; Montanari G; Nalli G; Luerti M
    Gynecol Oncol; 2006 Nov; 103(2):599-603. PubMed ID: 16750259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.
    Bonneterre J; Thürlimann B; Robertson JF; Krzakowski M; Mauriac L; Koralewski P; Vergote I; Webster A; Steinberg M; von Euler M
    J Clin Oncol; 2000 Nov; 18(22):3748-57. PubMed ID: 11078487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.
    Nabholtz JM; Buzdar A; Pollak M; Harwin W; Burton G; Mangalik A; Steinberg M; Webster A; von Euler M
    J Clin Oncol; 2000 Nov; 18(22):3758-67. PubMed ID: 11078488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative study of transvaginal ultrasonographic and diagnostic hysteroscopic findings in postmenopausal breast cancer patients treated with tamoxifen.
    Gao WL; Zhang LP; Feng LM
    Chin Med J (Engl); 2011 Aug; 124(15):2335-9. PubMed ID: 21933565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.